1Gerlach J,Ghosh S,Jumaa H,et al.B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22,an inhibitory coreceptor for BCR signalling[J].Eur J Immunol,2003,33(12):3418-3426. 被引量：1
3Stork B,Engelke M,Frey J,et al.Grb2 and the non-T cell activation linker NTAL constitute a Ca(2+)-regulating signal circuit in B lymphocytes[J].Immunity,2004,21(5):681-691. 被引量：1
4Mills DM,Stolpa JC,Cambier JC.Cognate B cell signalling via MHC class Ⅱ:differential regulation of B cell antigen receptorand MHC class Ⅱ/Ⅰg-alpha beta signalling by CD22[J].2004,172(1):195-201. 被引量：1
5Poe JC,Fujimoto Y,Hasegawa M,et al.CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms[J].Nat Immunol,2004,(10):1078-1087. 被引量：1
6Leonard JP,Coleman M,Ketas JC,et al.Phase Ⅰ/Ⅱ trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma[J].J Clin Oncol,2003,21(16):3051-3059. 被引量：1
7Linden O,Cavallin-Stahl E,Strand E,et al 90-Yttriumepratuzumab in patients with B-cell lymphoma failing chemotherapy,using a dose fractionation schedule[J].Cancer Biother Radiopharm,2005,20(4):457-466. 被引量：1
8Griffiths GL,Govindan SV,Sharkey RM,et al.90Y-DOTA-hLL2:an agent for radioimmunotherapy of non-Hodgkin's lymphoma[J].J Nucl Med,2003,44(1):77-84. 被引量：1
9Steinfeld SD,Tant L,Burmester GR,et al.Epratuzumab (a humanized anti-CD22 antibody) in primary sjogren's synclrome:an open-labed phase Ⅰ/Ⅱ study[J].Arthritis Res Ther,2006,20:8(4)R192. 被引量：1
10Vallera DA,Brechbiel MW,Bums LJ.Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody Clin Cancer Res,2005,11(21):7920-7928. 被引量：1
